WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H576936
CAS#: 64092-48-4 (sodium)
Description: Zomepirac sodium anhydrous is a prostaglandin synthetase inhibitor and is not an opioid, an opioid antagonist, or a salicylate.
Hodoodo Cat#: H576936
Name: Zomepirac sodium
CAS#: 64092-48-4 (sodium)
Chemical Formula: C15H13ClNNaO3
Exact Mass: 313.05
Molecular Weight: 313.710
Elemental Analysis: C, 57.43; H, 4.18; Cl, 11.30; N, 4.46; Na, 7.33; O, 15.30
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 33369-31-2 (free acid) 64092-48-4 (sodium) 64092-49-5 (sodium hydrate)
Synonym: Sodium zomepirac; Zomax, Zomepirac sodium, Zomepirac sodium anhydrous
IUPAC/Chemical Name: 1H-Pyrrole-2-acetic acid, 5-(4-chlorobenzoyl)-1,4-dimethyl-, sodium salt
InChi Key: SEEXPXUCHVGZGU-UHFFFAOYSA-M
InChi Code: InChI=1S/C15H14ClNO3.Na/c1-9-7-12(8-13(18)19)17(2)14(9)15(20)10-3-5-11(16)6-4-10;/h3-7H,8H2,1-2H3,(H,18,19);/q;+1/p-1
SMILES Code: O=C([O-])CC1=CC(C)=C(C(C2=CC=C(Cl)C=C2)=O)N1C.[Na+]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 313.71 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1. McEvoy GK. Evaluation of zomepirac sodium. Am J Hosp Pharm. 1981 Sep;38(9):1293-301. PMID: 7025615.
2. Muschek LD, Grindel JM. Review of the pharmacokinetics and metabolism of zomepirac in man and animals. J Clin Pharmacol. 1980 Apr;20(4):223-9. doi: 10.1002/j.1552-4604.1980.tb01702.x. PMID: 6769977.
3. McLeod DC. Zomepirac (Zomax, McNeil Pharmaceutical). Drug Intell Clin Pharm. 1981 Jul-Aug;15(7-8):522-30. doi: 10.1177/1060028081015007-802. PMID: 7018870.